By Beth Winegarner ( June 5, 2013, 6:48 PM EDT) -- A federal judge on Wednesday refused to toss a shareholder derivative suit against Abbott Laboratories, finding the plaintiffs had adequately argued Abbott's directors knew the company was in trouble for marketing off-label uses for the anti-seizure drug Depakote but did nothing, costing the company $1.6 billion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.